Current as of 6/1/2013. This document may not be part of the latest reprint MDA 020427/S-005 & NDA 022006/S-006



## OPHTHALMOLOGIC ASSESSMENT FORM



## **INSTRUCTIONS**

- 1. This form may be completed by either the prescriber or consultant ophthalmic professional. This form must be signed by the prescriber and faxed to SHARE for every patient at baseline (within 4 weeks of starting SABRIL).
- 2. For patients formally exempted from visual assessment due to blindness or irreversible neurological condition, subsequent forms are not required to be submitted.
- 3. For all other patients, follow-up assessment forms are required to be submitted at least every 90 days while the patient is taking SABRIL and approximately 3-6 months after discontinuation.
- 4. The diagnostic approach should be individualized according to each patient and/or clinical situation. Although attempts should be made to assess visual acuity and visual fields, no specific tests are required.
- 5. All fields must be completed.

## Completed forms should be faxed to the SHARE Call Center at 1-877-742-1002.

	NE: Patient Profile						
Name (First, Middl	ie, Last)			Sex	: 🗆 Male 🗆 Fem	ale DOB	
Address			_ City			_ State	_ ZIP
Patient currently	y on SABRIL: □YES □NO						
SECTION T	WO: Consultant Ophthalmi	c Profess	ional*				
Was an ophtha	Imic professional consulted?	TYES	🗖 NO				
Ophthalmic Prof	fessional Name (First, Middle Initial, La	ist)				NPI #_	
Address			_ City			_ State	ZIP
Phone				-			
	professional's name, printed),_ indicated below was conducte					, attes	t that the vision
Signature:						Date:	
*With experti	se in visual field interpretation and	d the ability	to perfor	m dilated indirec	t ophthalmoscopy	of the retina	а.
SECTION T	HREE: Ophthalmologic Ass	sessment					
1. Was an oph	thalmologic assessment condu	cted? □	YES _	month/day/y		🗆 NO	
If NO, for w	hich reason was an ophthalmol	ogic asses	sment n	ot conducted?			
🗇 P	Patient is blind (Checking this bo	x exempts µ	patient fro	om follow-up asse	essments)		
🗇 P	Patient's general neurological co	ondition pr	recludes	the need for vis	sual assessment		
	This condition is reverse	ible 🗆		ondition is irreve ng this box exemp	ersible pts patient from fo	ollow-up asse	essments)
O P	Patient's medical condition pred	cludes safe	e visual a	assessment (plea	ase explain)		
-	This condition is revers	ible 🗖	This co	ndition is irreve	ersible		

□ Other (please explain) \_

Assessment form continues on page 2

## Current as of 6/1/2013. This document may not be part of the approximation of the approximati

Assessment form continued from page 1 Patient Name (First, Middle, Last)
<ul> <li>If assessment occurred more than 1 month after the due date, please indicate the reason:</li> <li>Patient's financial/reimbursement situation</li> <li>Transportation issues</li> <li>Scheduling conflicts</li> <li>Other (please explain)</li> </ul>
2. Was a best-corrected visual acuity evaluation conducted?   YES  NO
If yes, please indicate the results: Left eye/ Right eye/
<b>3. Were the visual fields assessed?</b> □ YES □ NO
Was confrontational testing conducted?   YES  NO
Which method of visual field testing was used? (check all that apply)
<ul> <li>Kinetic: Goldmann, V4e isopter</li> <li>Kinetic: automated (SSA-kinetic test from Humphrey or Octopus perimeter menu: III4e isopter)</li> <li>Static automated threshold perimetry (to at least 60°)</li> <li>Other</li></ul>
Was this the same technique as used for baseline?
Please indicate the results by providing the estimated visual field extent in:
Temporal field ODdegrees from center Temporal field OSdegrees from center
Nasal field ODdegrees from center Nasal field OSdegrees from center
4. Other types of testing performed (Check all that apply. No specific tests are required and this question may be left blank.)
□ None □ Indirect ophthalmoscopy/Fundoscopy □ OCT □ ERG □ Other
SECTION FOUR: Prescriber Agreement and Signature
I (prescriber's name, printed),, agree that I have received and reviewed the vision assessment results for my patient and will submit this form to the SHARE Call Center.
Signature: Prescriber's NPI #: Date:
If formal perimetry or OCT was conducted, please attach a copy of the visual field recordings. www.LundbeckSHARE.com Fax to 1-877-742-1002

Lundbeck Inc., Deerfield, IL 60015. ©2011 Lundbeck Inc. Sabril and SHARE are registered trademarks of Lundbeck Inc. 09/2011 VGB077R4